1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Genfit S.A.

Genfit S.A.

GNFTF
Genfit S.A.US flagOther OTC
15.75
USD
- -
- -
788.04MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.09
0.07
0.02
0.01
- -
- -
0.83
0.02
1.8
0.41
0.57
1.33
- -
Basic EPS, GAAP
-0.63
-0.74
-0.69
-1.25
-1.79
-2.55
-1.76
-2.6
1.51
-0.48
-0.58
0.03
- -
Free Cash Flow per Basic Share
-0.47
-0.7
-0.63
-1.09
-1.69
-1.89
-1.34
-2.5
2.23
-1.47
-1.16
0.29
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.67
2.85
2.24
4.58
3.26
0.67
2.16
-0.42
2.39
1.9
1.36
1.38
-0.45
Tangible Book Value per Share
0.66
2.85
2.22
4.56
3.23
0.65
2.14
-0.43
2.39
1.01
0.39
0.42
-0.53
Basic Weighted Avg Shares
20
23
25
27
31
31
37
39
45
49
50
50
- -
Sales/Revenue/Turnover
2
2
1
- -
- -
- -
31
1
80
20
29
67
65
Operating Margin (%)
-548.51
-1,070.14
-3,353.13
-12,027.82
-48,039.83
-100,702.9
-187.58
-10,131.9
40.43
-135.26
-95.1
4.81
-81.86
Depreciation Expense
- -
- -
1
1
1
2
3
4
3
2
2
2
2
Net Income, GAAP
-13
-17
-17
-34
-56
-80
-65
-101
67
-24
-29
2
-86
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
3.19
- -
- -
18.41
- -
Profit Margin (%)
-666.15
-1,054.83
-3,251.42
-11,854.58
-47,227.12
-115,247.83
-211.24
-13,231.5
84
-117.45
-101.15
2.25
-131.38
Working Capital
18
73
58
144
256
179
247
154
205
119
75
18
72
LT Debt
6
5
4
5
162
166
179
181
72
70
62
6
108
Total Equity
14
70
55
143
101
21
84
-16
119
95
68
69
-23
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
15.96
- -
- -
1.92
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
39.75
- -
- -
3.99
- -
Return on Common Equity (%)
-120.92
-40.29
-27.23
-33.97
-45.63
-129.94
-124.08
- -
- -
-22.21
-35.57
2.2
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.3%
-200.86%
-132.56%
Free Cash Flow
-56.55%
-164.85%
-303.58%
Net Income, GAAP
-594.77%
-1,237.94%
-5,804.58%
Sales/Revenue/Turnover
5,481.6%
2,093.09%
-2.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
3
14
- -
29
2024
- -
- -
- -
- -
67
2025
- -
- -
- -
- -
65

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.58
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pascal Prigent
Full Time Employees
192
Sector
Healthcare
Industry
Biotechnology
Address
Parc EurasantE Loos HF France 59120
IPO Date
Jan 27, 2014
Website
genfit.com
Similar Companies
Lonza Group AG (0QNO.L)
Centessa Pharmaceuticals plc (CNTA)
Aptamer Group plc (APTA.L)
Atrium Therapeutics, Inc. (RNA)
Frontage Holdings Corporation (1521.HK)
Liminal BioSciences Inc. (LMNL)
Business
Genfit S.A., a biopharmaceutical firm, is dedicated to discovering and advancing therapeutic compounds and diagnostic innovations for significant metabolic and hepatic disorders. The company's lead compound, Iqirvo (elafibranor), has recently gained accelerated approval from the U.S. FDA in June 2024, followed by European Medicines Agency and MHRA approvals in September 2024, for the treatment of primary biliary cholangitis. Ipsen holds the global licensing rights for elafibranor, providing Genfit with milestone payments and royalties. Additionally, Genfit develops the NIS4 technology, a non-invasive blood test for identifying at-risk non-alcoholic steatohepatitis (NASH) and fibrosis, which powers Labcorp's commercially available NASHnext diagnostic. The pipeline also includes several programs focused on acute-on-chronic liver failure (ACLF), such as G1090N in Phase 1, and preclinical assets like SRT-015, CLM-022, and VS-02-HE, while development of VS-01 in ACLF was discontinued and is being re-prioritized for urea cycle disorder. Genfit also progresses GNS561, an investigational therapy for cholangiocarcinoma, through a collaboration with Genoscience Pharma. Established in 1999, Genfit S.A. is headquartered in Loos, France, and voluntarily delisted its American Depositary Shares from Nasdaq in November 2025.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Genfit S.A. (GNFTF) Discusses Developments and Guidance in MASH Diagnostics Transcript

  • globenewswire.com

    GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

  • globenewswire.com

    GENFIT: June 15, 2026 Combined Shareholders Meeting Results

  • globenewswire.com

    GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH